NuScale's 83% Crash Isn't A Discount — It's The Market Recognizing A Story Isn't Revenue

NuScale Power's stock has lost 83% from its 52-week high of $57.42 to around $9.70. The headline invites one question: after a decline this steep, is the nuclear renaissance trade available at a discount?

The answer depends on what kind of nuclear company you're looking at. The sector contains two entirely different businesses disguised under one narrative. One group owns operating reactors and sells electricity under contract. The other owns patents, engineering studies, and promises. The stock that fell 83% belongs to the latter. The drop isn't a mispricing — it's the market recognizing that a story, no matter how true, doesn't pay bills.

The Math NuScale Can't Paper Over

NuScale is the most advanced small modular reactor developer in the world. It holds the only NRC-certified SMR design in the industry, has built a supply chain of more than 60 specialized partners, and its technology has an exclusive global strategic partner in ENTRA1 Energy. None of that matters if you can't fund the next three years.

The numbers say the runway is thin. NuScale ended Q2 2026 with roughly $1.9 billion in cash, cash equivalents, and investments. Its trailing twelve-month free cash flow burn was $778.8 million. That gives it approximately two years of runway if spending stays flat. But the burn isn't flat — Q1 2026 operating cash outflow alone was $314.7 million, much of it from a $259.9 million capital deployment to ENTRA1. That's a one-time structure item, but the underlying operating cost is real.

Revenue isn't filling the gap. NuScale's Q1 2026 revenue was $565,000. Q2 was $75,000. For context, full-year 2025 revenue was $31.5 million. The company made more money in a single quarter of 2024 — $34.2 million in Q4 — from engineering services and technology licensing than it has in the first half of 2026 combined. The engineering work that generated that 2024 revenue is done.

At its current $4.2 billion market cap, NuScale trades at nearly 390 times its trailing revenue. That's a valuation multiple that belongs to a company growing at hyperbolic rates, not one earning $75,000 per quarter. The stock fell 83% from its peak and still prices in a future that doesn't exist yet.

The big idea behind NuScale's valuation is the Tennessee Valley Authority deal. ENTRA1 and TVA have a nonbinding collaborative agreement to deploy up to 6 gigawatts of NuScale SMR capacity across seven states. Nonbinding is the operative word. No definitive power purchase agreement has been signed. No revenue commitment exists. The timeline for when the first module might generate revenue — if the TVA deal materializes and manufacturing scales — runs in years, not quarters.

NuScale also has a project in Romania through RoPower Nuclear, with shareholder approval to deploy six modules at a former coal plant site. Again: advanced, but not revenue-producing.

The Nuclear Story That Isn't Broken

The sell-off swept across the entire sector. Oklo, the Sam Altman-backed reactor developer, fell 83% from its $193.84 peak to $41.27. The VanEck Uranium and Nuclear ETF (NLR) was down roughly 35% from its January 2026 peak. The market decided that AI-driven electricity demand was overblown, that hyperscaler capital spending would slow, and that every company priced on 2030 outcomes had no business existing today.

But the physical demand for baseload nuclear power hasn't cracked. Uranium long-term contract prices climbed to an all-time high of roughly $97 per pound. Thirty-eight countries pledged to triple nuclear capacity by 2050. Hyperscalers continue signing power purchase agreements for data centers, and the grid cannot meet the demand with intermittent sources alone.

The companies actually selling that power are telling a different story than the ones that just fell.

Constellation Energy — the largest U.S. producer of carbon-free energy, operating 24 nuclear reactors — is not a pre-revenue story. It generates real operating cash flow, pays a dividend, and has $106 billion in market value backed by actual electricity contracts. In Q2 2026 alone, Constellation signed roughly 920 megawatts of new long-term power purchase agreements, including a 15-year deal with Walmart for 176 MW of nuclear power from its Dresden Clean Energy Center.

Constellation's trailing twelve-month operating cash flow is $4.2 billion. Free cash flow, after $3.9 billion in capital expenditures to maintain and upgrade its fleet, was $309 million. Revenue grew 26% year over year. Gross margins sit at 44%. The company trades at roughly 30 times trailing earnings — expensive for a utility, but the market is pricing real growth, not a regulatory approval timeline.

Compare that to the two SMR developers. Oklo has a $7.7 billion market cap and zero revenue. It burned $276 million in free cash flow over the trailing twelve months, against $1.6 billion in cash. NuScale burned $779 million against roughly $766 million in cash equivalents. Both companies have negative earnings, negative cash flow, and valuations that assume their reactors will be built, licensed, financed, and operating — all before the investor sees a single watt of revenue.

The sell-off compressed the speculative valuations. It did nothing to the underlying problem: these companies have years between now and commercial electricity generation.

What the 83% Decline Actually Means

An 83% drop from peak is the kind of number that triggers bargain-hunting instincts. The instinct says: if the thesis is still true, buying at a fraction of the peak is free upside. The math says something different.

NuScale's decline from $57 to $9.70 reprices the market from "SMR deployment is imminent" to "SMR deployment is uncertain and expensive." The market is no longer assuming the TVA deal closes on schedule, that manufacturing scales without cost overruns, or that ENTRA1 can raise the billions needed to co-fund construction. None of these assumptions are unreasonable — they're just future events that don't show up on a balance sheet.

The key question is whether the demand thesis survives the timeline risk. The demand is real. The physical uranium market is tight. Long-term contracts trade at record prices. Countries and companies are actively committing to nuclear baseload. The SMR technology is the only NRC-certified design in its class. All of that remains true regardless of NuScale's stock price.

What changed is the market's tolerance for valuing pre-revenue development companies at multi-billion dollar market caps. That tolerance evaporated alongside the broader AI-adjacent momentum trade. Semiconductors, electrical equipment, metals, and small-cap reactor developers all got repriced in the same move. NuScale fell with the trade, not because its technology got worse.

But falling with a trade and being a buying opportunity are not the same thing. A company that burns $779 million annually, earns $75,000 per quarter, and hasn't signed a definitive revenue contract for its flagship project is not a beaten-down value. It's an option on a multi-year deployment timeline, and the option premium — the $4.2 billion market cap — is the price the market is willing to pay for that timeline today.

If you believe the SMR deployment will proceed on plan, the current price may be acceptable. If anything delays the TVA agreement, slows manufacturing readiness, or strains the ENTRA1 funding structure, the remaining runway shrinks and the math gets harder. There is no earnings floor, no contracted revenue stream, and no operating cash flow to cushion a setback.

The lesson from this selloff is not that nuclear stocks are all cheap after falling. It's that the nuclear sector separates cleanly into two investment profiles: utilities that sell power today and trade at growth multiples, and developers that sell a story tomorrow and trade like options. One can be bought on a pullback. The other needs the story to come true before the price makes sense.

NuScale's stock fell 83% because the market stopped pretending the story is already happening.